Sarepta jumps as data shows gene therapy slows decline in muscle‑wasting disease

Sarepta Therapeutics

26/01/2026 15:31

Updates

** Shares of genetic medicine maker Sarepta Therapeutics SRPT.O rise 12% to $23.57

** Co says its Elevidys gene therapy slowed Duchenne muscular dystrophy progression by 70% or more on key movement tests over three years vs an external control group

**  Co says boys treated at ages 4–7 maintained motor function through age 9, with average scores on a standard movement scale staying above baseline

** Oppenheimer analysts said while investors are generally skeptical of studies using external control groups, they expect the data to improve physician and patient perceptions of Elevidys' benefit-risk profile and help accelerate commercial uptake

**  SRPT's Elevidys is being developed for Duchenne muscular dystrophy — a rare muscle‑wasting disease where boys progressively lose muscle strength and eventually the ability to walk, co says

** Trial tested Elevidys against placebo in boys aged between 4 and 7 years who had not yet lost the ability to walk due to DMD, co says

** Shares fell ~82% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))